Non-Opioid Options for Managing Pain

Canada is in the midst of an opioid crisis. And even with growing awareness of the risks, opioids continue to be used extensively in the management of pain. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain recommends optimizing non-opioid pharmacotherapy and non-pharmacological therapy rather than a trial of opioids for patients with chronic, non-cancer pain (who are not currently taking opioids).

The challenge with this recommendation is knowing what the evidence says about the many different non-opioid options for treating pain. Are they effective? Are they safe? Are they readily available to patients?

To help support decisions about managing pain, CADTH has been reviewing the evidence on different treatment options for various types of pain through our Rapid Response service.

Here, you’ll find the highlights of many of these evidence reviews — all in one place.

For more information on CADTH’s response to the opioid crisis in Canada, visit cadth.ca/opioids. To access all of our evidence and full reports on the management of pain, visit cadth.ca/pain.
## Summary of Considerations for Practice

### Legend:

- **Green Circle**: Reasonable amount of evidence (although comparison with opioids may be lacking, making their place in therapy uncertain). Evidence indicates that risk of harms is low and/or side effects are mild to moderate.

- **Yellow Triangle**: Some evidence to indicate effectiveness, but it may be conflicting, mixed, or lower quality. Evidence on harms lacking or unclear.

- **Red Circle**: No evidence or evidence shows lack of effectiveness. Limited or no evidence on harms.

<table>
<thead>
<tr>
<th>Chronic Musculoskeletal Pain</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ Prolotherapy</td>
<td>4</td>
</tr>
<tr>
<td>▲ Occupational therapy using a biopsychosocial approach</td>
<td>4</td>
</tr>
<tr>
<td>▲ Cyclobenzaprine</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shoulder Tendinitis</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ Shockwave therapy</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chronic Neck Pain</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ Manual therapy</td>
<td>4</td>
</tr>
<tr>
<td>▲ Physiotherapy</td>
<td>5</td>
</tr>
<tr>
<td>● Transcutaneous electrical nerve stimulation (TENS)</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chronic Back Pain</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ Manual therapy</td>
<td>5</td>
</tr>
<tr>
<td>▲ Physiotherapy</td>
<td>5</td>
</tr>
<tr>
<td>▲ Occupational therapy using a biopsychosocial approach</td>
<td>6</td>
</tr>
<tr>
<td>▲ Prolotherapy</td>
<td>6</td>
</tr>
<tr>
<td>● ▲ Transcutaneous electrical nerve stimulation (TENS)</td>
<td>6</td>
</tr>
<tr>
<td>▲ Magnesium</td>
<td>6</td>
</tr>
<tr>
<td>▲ Cyclobenzaprine</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chronic Knee Pain (Osteoarthritis)</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Exercise</td>
<td>7</td>
</tr>
<tr>
<td>● Transcutaneous electrical nerve stimulation (TENS)</td>
<td>7</td>
</tr>
<tr>
<td>▲ Viscosupplementation</td>
<td>7</td>
</tr>
</tbody>
</table>
Other Lower Extremity Chronic Pain Conditions ................................................................. 8

- Shockwave therapy ........................................................................................................... 8

Migraine Prophylaxis ........................................................................................................... 8

- Magnesium ...................................................................................................................... 8

Neuropathic Pain ................................................................................................................ 8

- Delta-9-tetrahydrocannabinol/cannabidiol buccal spray .................................................. 8
- Gabapentin ....................................................................................................................... 9

Fibromyalgia ....................................................................................................................... 9

- Gabapentin ....................................................................................................................... 9
- Cyclobenzaprine .............................................................................................................. 9

Chronic Pain ....................................................................................................................... 9

- Multidisciplinary treatment programs ............................................................................. 9
- Behavioural and psychological interventions ................................................................... 9
- Home-based transcutaneous electrical nerve stimulation (TENS) .................................. 10
- Nabilone ......................................................................................................................... 10
- Delta-9-tetrahydrocannabinol/cannabidiol buccal spray .................................................. 10
- Medical cannabis ........................................................................................................... 10
# Chronic Musculoskeletal Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations and Cautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolotherapy (irritant injection therapy)</td>
<td>• Evidence suggests that dextrose prolotherapy for the management of musculoskeletal pain, including low back pain, tendinopathy, and osteoarthritis, may provide pain relief and improve physical function compared with saline injection control, exercise alone, or before prolotherapy treatment.</td>
<td>• Evidence of limited quality&lt;br&gt;• No evidence comparing prolotherapy with opioids</td>
</tr>
<tr>
<td>Occupational therapy using a biopsychosocial approach</td>
<td>• A multimodal approach may have a better effect on pain, disability, depression, and life satisfaction compared with usual care or no treatment.</td>
<td>• Considerable heterogeneity across studies&lt;br&gt;• Blinding was not possible so ascertainment bias is possible</td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td>• Comparative studies found similar outcomes for cyclobenzaprine compared with diazepam, nonsteroidal anti-inflammatory drugs, or other muscle relaxants for musculoskeletal pain.</td>
<td>• Higher-quality and longer-term studies needed&lt;br&gt;• Adverse effects, including drowsiness, dizziness, and dry mouth, occur frequently</td>
</tr>
</tbody>
</table>

# Shoulder Tendinitis

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shockwave therapy</td>
<td>• For calcific tendinitis of the shoulder, evidence suggests shockwave therapy using high energy is effective in reducing pain compared with placebo. ▲  ▼&lt;br&gt;• For non-calcific shoulder tendinitis, no significant benefit was observed with shockwave therapy compared with placebo or other treatments. ●</td>
<td>• No comparison with opioids or other treatments&lt;br&gt;• Adverse effects have been sparsely reported but include pain, small bruises and hematomas, petechial bleeding, and erythema at the site of application and are more common with high-energy shockwave therapy</td>
</tr>
</tbody>
</table>

# Chronic Neck Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manual therapy (manipulation, mobilization, massage, traction)</td>
<td>• Manipulation and mobilization appear to be effective for managing neck pain in adults.&lt;br&gt;• Massage may be beneficial for neck pain in adults.&lt;br&gt;• Traction may be beneficial for managing neck pain in adults.&lt;br&gt;• Two evidence-based guidelines recommend the use of manual therapies for chronic neck pain in adults including manipulation, mobilization, multimodal manual therapy, and massage.&lt;br&gt;• The guidelines both recommend not to use relaxation massage, strain-counterstrain therapy, and/or traction.</td>
<td>• Evidence is limited (studies were limited in duration, quality, and quantity)&lt;br&gt;• No evidence or recommendations for paediatric patients</td>
</tr>
</tbody>
</table>
## Chronic Neck Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Physiotherapy | • Physiotherapy for neck pain appears to be effective or, at the very least, neutral. | • The evidence was limited and largely low to moderate in quality, and no adverse effects were reported  
• No studies were identified that compared the clinical effectiveness of physiotherapy with opioids |
| Transcutaneous electrical nerve stimulation (TENS)  
(Home based or in a health care setting) | • In general, guidelines do not recommend TENS (not specific to home use) for knee osteoarthritis, chronic neck pain, or chronic low back pain. | • No comparison to opioids  
• Limited evidence on harms or adverse events  
• Limited evidence for specific types of chronic pain |

## Chronic Back Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Manual therapy  
(manipulation, mobilization, massage, traction) | • Spinal manipulation and soft tissue therapy may have positive effects on pain and function for chronic low back pain.  
• The effectiveness of spinal mobilization (often included as an adjunct to spinal manipulation) is uncertain.  
• Traction for low back pain with or without radiculopathy appears not to be effective.  
• No serious harms have been reported.  
• Three evidence-based guidelines provided recommendations supporting the use of manual therapy (including spinal manipulation) for chronic low back pain in adults.  
• One guideline recommended against the use of traction. | • Evidence is limited (studies were limited in duration, quality, and quantity)  
• No evidence or recommendations for paediatric patients |
| Physiotherapy | • Physiotherapy for neck and/or back pain appears to be effective or, at the very least, neutral. | • The evidence was limited and largely low to moderate in quality, and no adverse effects were reported  
• No studies were identified that compared the clinical effectiveness of physiotherapy with opioids |
# Chronic Back Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| **Occupational therapy using a biopsychosocial approach** | • Multidisciplinary biopsychosocial rehabilitation interventions seem to be more effective than usual care (i.e., pain medication and physical treatment) or physical treatments in decreasing pain and disability.  
• Multidisciplinary rehabilitation seems to be more effective than physical treatment in work absenteeism but not more effective than usual care. | • Considerable heterogeneity across studies  
• Blinding was not possible so ascertainment bias is possible |
| **Prolotherapy (irritant injection therapy)** | • Evidence suggests that dextrose prolotherapy for the management of musculoskeletal pain, including low back pain, may provide pain relief and improve physical function compared with saline injection control, exercise alone, or before prolotherapy treatment. | • Evidence of limited quality  
• No evidence comparing prolotherapy with opioids |
| **Transcutaneous electrical nerve stimulation (TENS) (In a health care setting or at home)** | • In general, guidelines do not recommend TENS for chronic low back pain.  
• Two guidelines recommend home-based TENS for chronic pain syndrome and chronic low back pain if TENS is shown to be effective in a clinical setting. | • No comparison with opioids  
• Limited evidence on harms or adverse events  
• Limited evidence for specific types of chronic pain |
| **Magnesium (Oral or IV via a health care professional)** | • Intravenous magnesium followed by oral magnesium may be beneficial for refractory chronic low back pain compared with placebo. | • Demonstrated in only one randomized controlled trial — more evidence is needed |
| **Cyclobenzaprine** | • Cyclobenzaprine may be more effective than placebo for patients with back pain. | • Higher-quality and longer-term studies needed  
• Adverse effects, including drowsiness, dizziness, and dry mouth, occur frequently |
## Chronic Knee Pain (Osteoarthritis)

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exercise</strong></td>
<td>• Exercise compared with no intervention, placebo, or minimal intervention for knee osteoarthritis appears to be effective.</td>
<td>• No evidence on subpopulations of patients with osteoarthritis of the knee</td>
</tr>
<tr>
<td></td>
<td>• In general, outcomes that improved with exercise included pain, physical function, physical performance, and stiffness (with some inconsistencies in the evidence).</td>
<td>• The variety of interventions, lengths of follow-up, and frequency or duration of exercise make it difficult to draw conclusions regarding the optimal approach to exercise</td>
</tr>
<tr>
<td></td>
<td>• An indirect comparison suggests that exercise may be comparable with opioids for the management of knee osteoarthritis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• There is limited reporting on potential adverse events; however, falling is the most commonly reported adverse event.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Evidence suggests that exercise is not associated with increased knee osteoarthritis progression.</td>
<td></td>
</tr>
<tr>
<td><strong>Transcutaneous electrical nerve stimulation (TENS)</strong></td>
<td>• In general, guidelines do not recommend TENS for knee osteoarthritis.</td>
<td>• No comparison with opioids</td>
</tr>
<tr>
<td>(In a health care setting or home-based device for purchase)</td>
<td></td>
<td>• Limited evidence on harms or adverse events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Limited evidence for specific types of chronic pain</td>
</tr>
<tr>
<td><strong>Viscosupplementation</strong></td>
<td>• Viscosupplementation with hyaluronic acid may be superior to intra-articular placebo, corticosteroids, and nonsteroidal anti-inflammatory drugs for improving knee pain and function without increasing adverse events.</td>
<td>• Results are inconsistent, studies had significant limitations, and clinical significance was uncertain</td>
</tr>
<tr>
<td>(a procedure to inject lubricating fluid into a joint)</td>
<td>• The majority of guidelines did not find sufficient evidence to make a recommendation for or against the use of viscosupplementation for knee osteoarthritis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Two guidelines recommend against its use, while other guidelines recommend viscosupplementation after failure of other treatments, or in older adults with a certain osteoarthritis grade.</td>
<td></td>
</tr>
</tbody>
</table>
## Other Lower Extremity Chronic Pain Conditions

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Shockwave therapy                    | • For plantar fasciitis, limited evidence suggests shockwave therapy is more effective than placebo, and equally effective as platelet-rich plasma injection, corticosteroid injection, or surgery.  
  • For greater trochanteric pain syndrome, limited evidence suggests that shockwave therapy is more effective than conservative treatment; but findings are inconsistent when comparing shockwave therapy with corticosteroid injection or home-based physical training.  
  • For patellar tendinopathy, limited evidence suggests that shockwave therapy is more effective than conservative treatment or equally effective as surgery; but findings were inconsistent comparing shockwave therapy with placebo or corticosteroid injection.  
  • For medial tibial stress syndrome (shin pain), the addition of shockwave therapy to either conservative treatment or to a running program had added benefit. | • Limited evidence  
  • No comparison with opioids and limited comparison with other treatments  
  • Adverse effects reported with shockwave therapy included skin reddening, bruising at the site of application, and local swelling and pain |

## Migraine Prophylaxis

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Magnesium (oral) | • There is a possible benefit of oral magnesium for migraine prophylaxis compared with placebo.  
  • In two guidelines, magnesium was recommended for migraine prophylaxis. | • Limited evidence  
  • Various dosing |

## Neuropathic Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta-9-tetrahydrocannabinol/cannabidiol buccal spray</td>
<td>• One guideline recommended third-line use of delta-9-tetrahydrocannabinol/cannabidiol buccal spray for patients uncontrolled on drug therapy.</td>
<td>• Lack of high-quality, longer-term research</td>
</tr>
</tbody>
</table>
## Neuropathic Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Gabapentin            | • Studies suggest a greater reduction in neuropathic pain with gabapentin compared with placebo in adults.  
• Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors in patients with painful diabetic neuropathy or post-herpetic neuralgia.  
• Low-quality studies suggest that gabapentin may improve pain and related sleep disturbances caused by HIV-associated sensory neuropathy. | • Only a moderate proportion of patients experienced substantial pain relief (assessed as a 50% reduction or more in pain intensity)  
• Low-quality and limited-duration evidence  
• There is the potential for misuse of gabapentin                                                                 |

## Fibromyalgia

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Gabapentin            | • Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors in patients with fibromyalgia. | • Low-quality and limited-duration evidence  
• There is the potential for misuse of gabapentin                                                                 |
| Cyclobenzaprine       | • Cyclobenzaprine may be more effective than placebo.  
• Comparative studies found similar outcomes for cyclobenzaprine compared with amitriptyline.                                                                                                                      | • Higher-quality and longer-term studies needed  
• Adverse effects, including drowsiness, dizziness, and dry mouth, occur frequently                                                                 |

## Chronic Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| Multidisciplinary treatment programs  | • Multidisciplinary management of chronic, non-malignant pain may lead to modest improvement for some (but not all) of the outcomes measured.  
• Three guidelines recommended multidisciplinary treatment for the management of chronic, non-malignant pain under specific circumstances.                                                    | • Unclear how it compares with other treatments  
• No evidence for paediatric patients  
• Limited reporting of adverse events                                                                 |
| Behavioural and psychological interventions | • Cognitive behavioural therapy, or CBT, was recommended across all included guidelines.  
• Other psychological interventions including hypnosis, relaxation, biofeedback, and mindfulness were also recommended in two or more guidelines.                                                      | • Whether these interventions are effective for different types of chronic pain is unclear                                                                 |

---

Non-Opioid Options for Managing Pain
## Chronic Pain

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Research Findings</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home-based transcutaneous electrical nerve stimulation (TENS)</td>
<td>• The evidence was mixed, limited in quantity, and inconclusive.</td>
<td>• No comparison with opioids</td>
</tr>
<tr>
<td></td>
<td>• Two guidelines recommend home-based TENS for chronic pain syndrome if TENS is</td>
<td>• Limited evidence on harms or adverse events</td>
</tr>
<tr>
<td></td>
<td>shown to be effective in a clinical setting.</td>
<td>• Limited evidence for specific types of chronic pain</td>
</tr>
<tr>
<td>Nabilone</td>
<td>• Evidence suggests some positive benefits and limited harms of nabilone compared</td>
<td>• Evidence is limited and low quality</td>
</tr>
<tr>
<td></td>
<td>with placebo or known analgesics.</td>
<td></td>
</tr>
<tr>
<td>Delta-9-tetrahydrocannabinol/cannabidiol buccal spray</td>
<td>• Delta-9-tetrahydrocannabinol/cannabidiol buccal spray may be associated with</td>
<td>• Sustained benefit of short-term clinical outcomes and safety over a longer</td>
</tr>
<tr>
<td></td>
<td>favourable short-term patient outcomes, including reduced levels of perceived</td>
<td>term is unclear, and the clinical effectiveness of Delta-9-</td>
</tr>
<tr>
<td></td>
<td>pain and good tolerability, when compared with placebo therapy.</td>
<td>tetrahydrocannabinol/cannabidiol buccal spray oral spray in comparison with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>other pharmacologic treatments is lacking</td>
</tr>
<tr>
<td>Medical cannabis</td>
<td>• Medical cannabis may decrease the need for opioids, nonsteroidal anti-inflammatory</td>
<td>• Data are limited</td>
</tr>
<tr>
<td></td>
<td>drugs, tricyclic antidepressants, dexamethasone, and ondansetron when used</td>
<td></td>
</tr>
<tr>
<td></td>
<td>concomitantly.</td>
<td></td>
</tr>
</tbody>
</table>
Questions or comments about CADTH or our evidence?

Online: cadth.ca
Email: requests@cadth.ca
Twitter: @CADTH_ACMTS

New at CADTH Newsletter: cadth.ca/subscribe

DISCLAIMER
This material is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose; this document should not be used as a substitute for professional medical advice or for the application of professional judgment in any decision-making process. Users may use this document at their own risk. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not guarantee the accuracy, completeness, or currency of the contents of this document. CADTH is not responsible for any errors or omissions, or injury, loss, or damage arising from or relating to the use of this document and is not responsible for any third-party materials contained or referred to herein. Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada’s provincial or territorial governments, other CADTH funders, or any third-party supplier of information. This document is subject to copyright and other intellectual property rights and may only be used for non-commercial, personal use or private research and study.

ABOUT CADTH
CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Ce document est également disponible en français.

February 2019